April 2015—Qiagen announced the CE-IVD marking of its novel liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples to assess a genomic mutation in patients with non-small cell lung cancer.
The Therascreen EGFR RGQ Plasma PCR kit, co-developed by Qiagen and AstraZeneca, is designed to help physicians identify advanced NSCLC patients who could benefit from treatment with Iressa when a suitable tumor sample is not available. The test uses Qiagen’s QIAamp Circulating Nucleic Acid Kit for DNA purification, and analysis is based on an adapted version of the Therascreen EGFR RGQ PCR kit, which has been validated and commercialized for use with formalin-fixed, paraffin-embedded solid tumor samples. The test is performed on the company’s Rotor-Gene Q PCR detection platform.
Qiagen , 240-686-7425